CAU
ABCL icon

Caxton Associates (UK)’s AbCellera Biologics ABCL Stock Holding History

Caxton Associates (UK)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$521K Buy
+66,378
New +$324K 0.01% 528
2025
Q4 		– Sell
-357,506
Closed -$1.8M – 755
2025
Q3 		$1.8M Buy
+357,506
New +$1.58M 0.04% 221

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Caxton Associates (UK)'s ABCL Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 66,378 shares worth $521K. The stake represents 0.01% of the portfolio and ranks #528 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in ABCL as recently as Q3 2025.

Caxton Associates (UK) first reported a position in ABCL in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.8M in Q3 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Caxton Associates (UK) held 66,378 shares of AbCellera Biologics worth $521K as of Q2 2026.
  • AbCellera Biologics was a new Caxton Associates (UK) position in Q2 2026.
  • AbCellera Biologics made up 0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #528 holding.
  • Caxton Associates (UK) first reported a position in AbCellera Biologics in Q3 2025 and has held it in 2 quarters since.
  • Caxton Associates (UK)'s AbCellera Biologics position peaked at $1.8M in Q3 2025.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.